US EditionRevolutionary drug slashes major heart disease risk by over 90%
Summary by Ynet News
1 Articles
1 Articles
All
Left
1
Center
Right
Revolutionary drug slashes major heart disease risk by over 90%
Eli Lilly’s Lepodisiran shows unprecedented reduction in hereditary heart disease risk, sparking Phase 3 trials to validate long-term clinical benefits and redefine treatment for high Lp(a) patients; patients in Israel are participating in Phase 3 trial
·Tel Aviv-Yafo, Israel
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
